Massachusetts General Hospital
Department of Pharmacy
Department of Nursing
Critical Care
| Generic Name: | Abiciximab |
| Trade Name: | ReoproŽ |
| Action: | Glycoprotein IIB/IIIA inhibitor/preventing platelet adhesion and aggregation |
| Indications: | Prevent thrombus formation post PTCA and post stent placement. |
| Precautions and Side Effects: | Bleeding complications and thrombocytopenia are common side effects. |
| Allergic reaction: | Anaphylaxis may occur; hypotension with bolus dose |
| Standard Concentrations: | 9 mg / 250 ml |
| Administration Guidelines: | Bolus-0.25mg/kg administered
10-60minutes prior to PTCA.
Bolus-withdraw through the 0.2 or 0.22 micron low protein-binding filter the appropriate amount of ReoproŽ for the patient’s weight, 0.25mg/kg. Infusion-withdraw 4.5ml through the Millipore filter into a syringe. Inject into 250cc bag of NS & infuse at a rate of 0.125mcg/kg/min to max 10mcg/min. The IV tubing must have a filter on it (0.2 or 0.22 micron low protein-binding filter) & no other meds. should be piggybacked through this line. |
revised 08/07